Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Go-CHOP in Intestinal T-cell Lymphoma
NCT06701344Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib in enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and intestinal T-cell lymphoma (ITCL), sponsored by Ruijin Hospital. Primary endpoint: Complete Response Rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
enteropathy-associated T-cell lymphoma (EATL)monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL)intestinal T-cell lymphoma (ITCL)
Beyond the preview
Go deeper on NCT06701344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701344.